Overview

Sphenopalatine Ganglion Blockade in Migraine

Status:
Not yet recruiting

Trial end date:
2023-01-01

Target enrollment:
0

Participant gender:
All

Summary

Migraine is a fairly common disease that is a leading cause of disability worldwide. 15% of the general population suffer from migraine headaches. Although there are currently many options for the treatment of acute migraine, these treatment options, such as acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS), triptans, combinations analgesics and antiemetics, have insufficient efficacy and significant side effects. Therefore, there is a need for new treatment modalities in migraine. Sphenopalatine ganglion (SPG) block is gaining interest as an effective treatment for migraine, other headaches and facial pain syndromes. In our study, we aimed to block the Sphenopalatine ganglion with a local anesthetic drug and compare it with the placebo control group.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Afyonkarahisar Health Sciences University

Treatments:

Lidocaine

Criteria

Inclusion Criteria:

- Having a diagnosis of episodic migraine (according to ICD-III)

- Receiving any prophylaxis treatment in the last 3 months,

Exclusion Criteria:

- Being pregnant and lactating

- Neurological and psychiatric conditions (

- Contraindications to the use of local anesthetics

- Other chronic painful conditions,

- Having a history of malignancy